|
Somu Subramaniam is the Managing Partner of New Science Ventures (NSV), which he co-founded in 2004. NSV focuses on science-based venture investments in biotechnology, medical device and semiconductor sectors, and manages over $100 million and nearly 20 portfolio companies. Mr. Subramaniam serves on several Board of Directors, including Therox, a company that has developed a focal hyperoxemic technology designed to treat ischemic myocardial tissue in heart attack patients; BioVex, a biotechnology company focused on the development of novel biologics for the treatment of cancer and infectious disease; and Achronix a fabless semiconductor company building the world’s fastest FPGAs. He also is an observer to the boards of Light Sciences Oncology, Xoft and BioProcessors. Prior to starting NSV, Somu was a Director of McKinsey & Co. and at various times led their Strategy Practice, BioTechnology Practice and HealthCare Practice. He also was a member of McKinsey's Investment Committee. Somu received his undergraduate degree from B.Tech. from IIT and his M.B.A. from Harvard Business School. | 